Skip to content
GLP1-US
Prices checked Wegovy pill $149 Wegovy pen $349 Zepbound $299–449 Foundayo from $149 Ozempic $349 Medicare Bridge $50 Compounded sema $175 All prices →

Trial data checked Oct 17, 2026

Retatrutide vs Tirzepatide: What the Trials Show in 2026

Retatrutide led to more weight loss than tirzepatide in separate trials, but it is not FDA-approved and has no launch date. Tirzepatide (Zepbound) is available now from $299/mo.

  • Retatrutide not FDA-approved
  • Head-to-head TRIUMPH-5 running
  • Both weekly injections
  • Both from Lilly

We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure

By GLP1-US Editorial TeamUpdated
★ Editor's Choice
Chia Health logo

Chia Health

Our #1 pick for GLP-1 weight loss online

  • One monthly price: clinician, medication and free shipping included
  • Semaglutide or tirzepatide, as a weekly injection or a daily tablet
  • No insurance needed; HSA/FSA and Klarna accepted

Compounded medications, not FDA-approved. Prices checked Nov 17, 2026. Advertiser Disclosure

$212.89 first month, then $349/mo

6-month plan: $249/mo, paid upfront ($1,396.89 for the first 6 months). Microdose: $109.19 first month, then $179/mo.

Get Started Read our Chia Health review

01 At a glance

Retatrutide vs Tirzepatide at a Glance

Both drugs come from Eli Lilly, and both are once-weekly injections. The difference that matters most today is legal status: one is sold in pharmacies, the other exists only inside clinical trials.

RetatrutideTirzepatide
MakerEli LillyEli Lilly
ReceptorsGIP + GLP-1 + glucagonGIP + GLP-1
FDA statusInvestigational. Lilly plans to file its application in Q1 2027Approved: Mounjaro (type 2 diabetes) May 2022, Zepbound (weight) Nov 2023
FormWeekly injection (in trials)Weekly injection, single-dose vial or KwikPen
Doses4, 9 and 12 mg studied in trials2.5 to 15 mg on the FDA label
Brand namesNoneZepbound, Mounjaro
Legal accessClinical trial or Lilly expanded access onlyRetail pharmacy, LillyDirect, telehealth prescribers
CompoundingNot allowed under federal law (FDA)Compounded copies exist; they are not FDA-approved

Full background on the investigational drug: retatrutide FDA status and trials. The two tirzepatide brands explained: Mounjaro and Zepbound.

02 Mechanism

Tirzepatide vs Retatrutide: How They Work

GLP-1 receptor
Appetite and fullness, slower stomach emptying
Retatrutide Tirzepatide
GIP receptor
Insulin release after meals
Retatrutide Tirzepatide
Glucagon receptor
Energy use and liver fat
Retatrutide Tirzepatide: not targeted

"GLP-3" is an internet nickname for retatrutide, not a real hormone or receptor. People use it because retatrutide is a triple agonist (also called "triple G"), one step beyond tirzepatide's two receptors. There is no GLP-3 in the body. More on the name and the sellers using it: what GLP-3 means.

The glucagon part is the new piece, and it brings a new watch item. In the phase 2 trial published in NEJM in 2023, heart rate rose with dose and peaked around week 24 before easing. Background reading: how GLP-1 drugs work and is Zepbound a GLP-1.

03 Weight loss

Weight Loss: Retatrutide vs Tirzepatide Trial Results

Trials count weight loss two ways. The efficacy estimand assumes everyone stayed on the drug; the treatment-regimen estimand counts everyone randomized, including people who stopped.

Chart A: Efficacy estimand

Retatrutide 12 mg, TRIUMPH-1, 80 wk28.3%
Tirzepatide 15 mg, SURMOUNT-1, 72 wk22.5%

Placebo 2.2% (TRIUMPH-1) and 2.4% (SURMOUNT-1).

Chart B: Treatment-regimen estimand

Retatrutide 12 mg, TRIUMPH-1, 80 wk25.0%
Tirzepatide 15 mg, SURMOUNT-1 (Zepbound label), 72 wk20.9%

Placebo 3.9% (TRIUMPH-1) and 3.1% (SURMOUNT-1).

Chart C: With type 2 diabetes, efficacy estimand

Retatrutide 12 mg, TRIUMPH-2, 80 wk20.8%
Tirzepatide 15 mg, SURMOUNT-2, 72 wk15.7%

Placebo 4.0% (TRIUMPH-2) and 3.3% (SURMOUNT-2).

Separate trials, different lengths (80 vs 72 weeks). Not head-to-head. Each chart uses one estimand only.

At the top doses, retatrutide is about 4 to 6 percentage points ahead depending on the estimand, but its trials ran 8 weeks longer. Lower retatrutide doses overlap with tirzepatide: 4 mg gave 19.0% and 9 mg gave 25.9% in TRIUMPH-1 (efficacy estimand). A subgroup with a BMI of 35 or higher that stayed on to week 104 reached 30.3% on 12 mg, which is why some headlines say "30%". For the TRIUMPH-2 detail, see our TRIUMPH-2 full results report.

See what tirzepatide costs now

04 Side effects

Side Effects Compared

Adverse eventRetatrutide 12 mg (TRIUMPH-1)Zepbound 5 to 15 mg (FDA label)
Nausea42.4% (placebo 14.8%)25 to 29% (placebo 8%)
Diarrhea32.0% (placebo 13.5%)19 to 23% (placebo 8%)
Constipation26.1% (placebo 10.9%)11 to 17% (placebo 5%)
Vomiting25.3% (placebo 4.8%)8 to 13% (placebo 2%)
Dysesthesia (odd skin sensations)12.5% (placebo 0.9%)Not a listed common reaction
Stopped for side effects11.3% (placebo 4.9%)4.8 to 6.7% (placebo 3.4%)

Stomach side effects lead on both drugs, and both are dose-related. Retatrutide 12 mg roughly doubled the vomiting rate of top-dose Zepbound in these separate trials, and more than 1 in 10 people stopped it. Only tirzepatide has a final FDA label, which carries a boxed warning for thyroid C-cell tumors; retatrutide's full safety profile is still under review. Our Zepbound side effects guide covers the label warnings in plain English.

Ask a PlushCare doctor about tirzepatide side effects

Self-pay visit $129, insured visits typically $30 copay or less (PlushCare, Oct 2026).

05 Head to head

The Head-to-Head Trial: TRIUMPH-5

  1. Registered

    NCT06662383: phase 3, randomized, double-blind, retatrutide vs tirzepatide in adults with obesity.

  2. Enrolled

    About 800 participants (estimated). Status: active, not recruiting.

  3. Measures

    Percent change in body weight at week 80.

  4. Nov 2026 (estimated)

    Primary completion; study completion estimated Dec 2026.

TRIUMPH-5 is the first trial that puts the two drugs side by side with one protocol, one population and one estimand. Results are not public yet. When Lilly reports them, we will cover the numbers in GLP-1 news and update this page.

06 Availability

Cost and Availability

Retatrutide

No price, not on sale

  • Not approved, and Lilly has announced no price.
  • The FDA says retatrutide cannot be used in compounding under federal law.
  • Vials sold online as "research use only" or "not for human consumption" are unapproved drugs; the FDA has sent warning letters to sellers and to telehealth companies marketing retatrutide.
  • The only legal routes are a clinical trial or Lilly's expanded access program (see the next section).

Tirzepatide, Zepbound

$299 to $449/mo self-pay

  • LillyDirect self-pay, vial or KwikPen: 2.5 mg $299, 5 mg $399, 7.5 to 15 mg $449 when you refill within 45 days (otherwise $499 for 7.5 mg, $699 for 10 to 15 mg).
  • Savings card with commercial coverage: as little as $25 a month (expires Dec 31, 2026).
  • Medicare GLP-1 Bridge: $50 a month for the KwikPen, Jul 1, 2026 to Dec 31, 2027, for eligible Part D members.
  • Compounded tirzepatide is not FDA-approved. See compounded tirzepatide.

Prices as of Oct 2026 from zepbound.lilly.com and CMS; they can change. Telehealth programs add a membership on top: at Hers it is $149 a month after a $39 first month.

07 Decision

Should You Wait for Retatrutide?

  • Timeline. Lilly plans to file in Q1 2027. With a standard FDA review of about a year, late 2027 is the earliest realistic US launch.
  • Switching later. Starting an approved drug now does not rule out a change once retatrutide is approved. Your prescriber decides if and when.
  • Cost of waiting. A year or more without treatment is a year of untreated weight-related risk, while Zepbound is available today from $299/mo.
  • Expanded access is narrow. It is limited to adults with a BMI of 35 or higher despite the highest available dose of a weight drug, plus 2 or more serious obesity-related complications, on a physician's request.
  • No self-sourcing. Any retatrutide outside a trial is an unapproved product of unknown content.

If you want to start now, the legal options for tirzepatide are a retail pharmacy prescription, LillyDirect, or a telehealth prescriber. We compare them in tirzepatide online.

Talk to Ro about starting Zepbound now

Ro bills a membership ($39 first month, then $74 to $149/mo) plus Zepbound at LillyDirect self-pay prices (Oct 2026).

Medical Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.

08 FAQ

Retatrutide vs Tirzepatide FAQ

Is retatrutide better than tirzepatide?
In separate trials, retatrutide produced more weight loss: 28.3% at 80 weeks on 12 mg in TRIUMPH-1, against 22.5% at 72 weeks on tirzepatide 15 mg in SURMOUNT-1, both on the efficacy estimand. It also had more dropouts, with 11.3% stopping for side effects. No head-to-head result exists yet, and only tirzepatide is FDA-approved and sold in the US.
Tirzepatide vs retatrutide: which has more side effects?
Retatrutide had higher rates in trials. On 12 mg, 42.4% of people had nausea, 25.3% vomited and 11.3% stopped because of side effects. On the Zepbound label, tirzepatide nausea was 25 to 29%, vomiting 8 to 13% and discontinuation 4.8 to 6.7%. The trials were separate, so the gap is a signal, not a direct comparison. TRIUMPH-5 will compare them directly.
What is GLP-3 retatrutide?
"GLP-3" is an online nickname, not a hormone. Retatrutide acts on 3 receptors: GLP-1, GIP and glucagon, which is why it is also called a triple agonist or "triple G". Tirzepatide acts on 2 of them, GIP and GLP-1. There is no GLP-3 receptor in the body, so the name describes the number of targets, not a new hormone.
Is retatrutide FDA approved?
No. As of October 2026 retatrutide is investigational. Lilly plans to submit a Biologics License Application in Q1 2027, and FDA reviews usually take about a year. Until approval, no US pharmacy or clinic can legally dispense it outside a clinical trial or Lilly's expanded access program, and the FDA says it cannot be compounded.
Can I switch from tirzepatide to retatrutide?
Not outside a clinical trial or Lilly's expanded access program. Expanded access is limited to adults with a BMI of 35 or higher despite the highest available dose of a weight drug, plus 2 or more serious obesity-related complications, requested by a physician. For everyone else, staying on approved tirzepatide with a prescriber is the legal path until retatrutide is approved.
Is there a head-to-head study of retatrutide vs tirzepatide?
Yes. TRIUMPH-5 (NCT06662383) compares retatrutide with tirzepatide in about 800 adults with obesity and measures weight change at week 80. It is active but no longer recruiting, with primary completion estimated for November 2026 and study completion for December 2026. Results are not public yet.
How much does tirzepatide cost compared with retatrutide?
Zepbound (tirzepatide) costs $299 to $449 a month self-pay through LillyDirect as of Oct 2026: $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg with a refill within 45 days. With a covered commercial plan, the savings card can bring it to $25. Retatrutide has no price because it is not approved.
Checked against primary sources such as FDA labels, CMS and provider pages
Updated
How we check facts →